Pharmacological treatment of irritable bowel syndrome: a critical assessment

References

• Drossman DA, Li Z, Andruzzi E, Talley NJ, Thompson WG, Whitehead WE, et al. US householder survey of functional GI disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569–80.
   PubMed Web of Science ®Google Scholar
• Farting MJG. Irritable bowel, irritable body or irritable brain? Br Med J 1995;310:171–5.
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 11:1143–7.
   Google Scholar
• Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3–15.
   PubMed Web of Science ®Google Scholar
• Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48: 272–82.
   PubMed Web of Science ®Google Scholar
• Pace F, Coremans G, Dapoigny M, Muller-Lissner SA, Smout A, Stockbrugger RW, et al. Therapy of irritable bowel syndrome. An overview. Digestion 1995;56:433–42.
   Google Scholar
• Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653–4.
   PubMed Web of Science ®Google Scholar
• Thompson WG, Dotevall G, Drossman D, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Report of the Rome Working Team. Gastroenterol Int 1989;2:92–5.
   Google Scholar
• Talley NJ, Nyren O, Drossman DA, Heaton KW, Veldhuyzen van Zanten SJO, Koch MM, et al. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993;6:189–211.
   Google Scholar
• Maxton DG, Morris J, Whorwell PJ. Improving clinical trials in irritable bowel syndrome: some practical aspects. Eur J Gastroenterol Hepatol 1992;4:337–41.
   Google Scholar
• Bijkerk CJ, deWit NJ, Muris JW, Jones RH, Knotterus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98:122–7.
   PubMed Web of Science ®Google Scholar
• Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987;28:1510–3.
   PubMed Web of Science ®Google Scholar
• Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 511–4.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Caroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical tials: is blinding necessary? Controlled Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136–47.
   Google Scholar
• Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolized guar gum (PHGG). Dig Dis Sci 2002;47:1697–704.
   PubMed Web of Science ®Google Scholar
• Passaretti S, Guslandi M, Imbimbo BP, Daniotti S, Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1989;3:267–76.
   Google Scholar
• Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double-blind placebo-controlled trial. Gut 1990;31:355–8.
   PubMed Web of Science ®Google Scholar
• Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002;14:1331–8.
   PubMed Web of Science ®Google Scholar
• Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol 1998;93: 1131–5.
   PubMed Web of Science ®Google Scholar
• Poynard T, Reginbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355–61.
   Google Scholar
• Clouse RE. Antidepressants for functional intestinal syndromes. Dig Dis Sci 1994;39:2352–63.
   PubMed Web of Science ®Google Scholar
• Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409–16.
   PubMed Web of Science ®Google Scholar
• Barbier JP, Dorf G, Gordin J, Krainik F, Neveu D, Parlier H, et al. Effect of a buzepide metiodide-haloperidol combination in treating functional intestinal disorders. Randomised double-blind controlled versus placebo study. Ann Gastroenterol Hepatol Paris 1989;3:123–8.
   Google Scholar
• Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol Suppl 1989;2:S66–76.
   Web of Science ®Google Scholar
• Jackson JL, O’Malley pG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108: 65–72.
   Google Scholar
• Kilkens TO, Honig A, Rozendaal N, Van Nieuwenhoven MA, Brummer RJ. Serotoninergic modulators in the treatment of irritable bowel syndrome: influence on psychiatric and gastrointestinal symptoms. Alim Pharmacol Ther 2003;17:43–51.
   Google Scholar
• Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303–17.
   PubMed Web of Science ®Google Scholar
• De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001;61:317–32.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Safety concerns about alosetron. Arch Intern Med 2002;162:100–1.
   PubMedGoogle Scholar
• Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035–40.
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Bodemar G, Geldhof H, Schutz E, Heath A, Mills JG, et al. A double-blind, randomized, placebo-controlled dose ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23–34.
   PubMed Web of Science ®Google Scholar
• Muller-Lissner SA, Fumagalli I, Barhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15: 1655–66.
   Google Scholar
• Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16: 1877–88.
   PubMed Web of Science ®Google Scholar
• Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantanum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47: 2615–20.
   PubMed Web of Science ®Google Scholar
• Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebocontrolled trial. Aliment Pharmacol Ther 2002;16:1187–95.
   Google Scholar
• Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome: a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649–54.
   PubMed Web of Science ®Google Scholar
• Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma-lax, a Tibetan herbal formula. Digestion 2002;65:161–71.
   PubMed Web of Science ®Google Scholar
• Hubner WD, Moser EH. Charcoal tablets in the treatment of patienta with irritable bowel syndrome. Adv Ther 2002;19:245–52.
   PubMed Web of Science ®Google Scholar
• Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut2000;47 Suppl II:ii1–19.
   Google Scholar
• Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97 Suppl:S7–26.
   Google Scholar
• Bassotti G, Whitehead WE. Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. Q J Med 1997;90:545–50.
   Google Scholar
• Palsson OS, Whitehead WE. The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders. Gastroenterology 2002;123:2132–5.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Spiller RC. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555–64.
   PubMed Web of Science ®Google Scholar
• Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972–9.
   PubMed Web of Science ®Google Scholar